Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPUARE)

Drug Name
2-(Phenylamino)-6-(3-acetamidophenyl)pyrazine Drug Info
Synonyms CHEMBL425576; 2-(Phenylamino)-6-(3-acetamidophenyl)pyrazine; SCHEMBL1122285
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
11515006
TTD Drug ID
DMPUARE

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting B-Raf messenger RNA (BRAF mRNA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MLN2480 DMBR8NF Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
RG7304 DMGFAVQ Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
SPN-803 DM8O2AQ Parkinson disease 8A00.0 Phase 1 [2]
PLX-4720 DMBK9AM Cutaneous melanoma 2C30 Phase 1 [4]
L-779450 DM51B74 Discovery agent N.A. Investigative [5]
ZM-336372 DMD5JYQ Discovery agent N.A. Investigative [6]
PLX-ORI3 DMZG1L5 Solid tumour/cancer 2A00-2F9Z Investigative [2]
ISIS 13741 DMC7Q38 Discovery agent N.A. Investigative [7]
ISIS 14144 DMWIKD5 Discovery agent N.A. Investigative [7]
PMID26061392C2 DMHZOIU Discovery agent N.A. Investigative [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-Raf messenger RNA (BRAF mRNA) TT0EOB8 BRAF_HUMAN Inhibitor [1]

References

1 Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead. J Med Chem. 2006 Jan 12;49(1):407-16.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1943).
3 Clinical pipeline report, company report or official report of Roche.
4 Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011 Oct 30;29(11):1046-51.
5 The identification of potent and selective imidazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett. 2006 Jan 15;16(2):378-81.
6 The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
7 US patent application no. 5,981,731, Antisense oligonucleotide modulation of B-raf gene expression.
8 Photoactivatable Prodrugs of Antimelanoma Agent Vemurafenib. ACS Chem Biol. 2015 Sep 18;10(9):2099-107.